DrStockPick.com Stock Report!
Friday August 7, 2009
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) announced today the completion of its previously announced public offering of 19,000,000 shares of its common stock at a price of $1.75 per share. ARIAD also announced that the underwriters have exercised in full their over-allotment option for the purchase of an additional 2,850,000 shares. Net proceeds of the public offering and the over-allotment option, a total of 21,850,000 shares, are approximately $35.6 million after underwriting discounts and commissions and estimated expenses.
Smithfield Foods, Inc. (NYSE: SFD) (the “Company”) announced today that it is initiating an offering, subject to market and other conditions, of $225 million of 10% senior secured notes due 2014. The notes will have identical terms and conditions, other than issue date and issue price, as the $625 million of 10% senior secured notes due 2014 issued by the Company on July 2, 2009. The Company intends to use the proceeds from the notes offering, together with other available cash, to repay other outstanding indebtedness.
Community Central Bank Corporation (Nasdaq:CCBD), the holding company for Community Central Bank, today reported results for the quarter and six months ended June 30, 2009. As of June 30, 2009, the Corporation and Bank were considered to be “Well Capitalized,” the highest regulatory capital level.
Weatherford International Ltd. (NYSE: WFT) today announced that it has scheduled a conference call for Monday, October 19, 2009 at 8:30 a.m. eastern, 7:30 a.m. central. The purpose of the conference call is to discuss results for the company’s third quarter ended September 30, 2009. The call will be open to the public.
Boeing (NYSE: BA) has named Andrew Ward as its new chief investment officer, a position from which he will oversee approximately $65 billion in retirement assets for approximately 550,000 beneficiaries.
GenTek Inc. (Nasdaq:GETI) today announced results for the second quarter ended June 30, 2009. For the second quarter of 2009, GenTek had revenues totaling $126.8 million and operating profit of $33.5 million. This compares to revenues of $151.5 million and operating profit of $13.3 million in the prior-year period. The significant improvement in year over year operating profit is primarily due to the results in the performance chemicals segment. Performance chemicals continues to benefit from the combined impact of selling price increases implemented over the course of 2008 coupled with moderating raw material costs. The Company recorded income from continuing operations of $22.2 million, or $2.17 per diluted share, compared to income from continuing operations of $8.3 million, or $0.74 per diluted share, in the second quarter of 2008.
Source: E-Gate System from Alphatrade.com
No comments:
Post a Comment